Detalles de la búsqueda
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674077
2.
TiLoop Bra Assisted Breast Reconstruction - Our Experience.
Chirurgia (Bucur)
; 116(2 Suppl): 84-90, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963697
3.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171426
4.
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Br J Cancer
; 120(6): 579-586, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30783204
5.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
N Engl J Med
; 372(8): 724-34, 2015 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25693012
6.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179402
7.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
; 384(9938): 164-72, 2014 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24529560
8.
Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields.
Rep Pract Oncol Radiother
; 20(1): 27-31, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25535581
9.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24657003
10.
Challenges to effective cancer control in China, India, and Russia.
Lancet Oncol
; 15(5): 489-538, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24731404
11.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 14(6): 461-71, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23602601
12.
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Lancet Oncol
; 14(10): 962-70, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23965225
13.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 379(9816): 633-40, 2012 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22257673
14.
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Breast Cancer Res Treat
; 142(1): 89-99, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24129974
15.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Lancet Oncol
; 13(9): 869-78, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22884505
16.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol
; 13(1): 25-32, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22153890
17.
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Eur J Cancer
; 181: 92-101, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36641898
18.
High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.
Int J Cancer
; 130(12): 2867-73, 2012 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21815139
19.
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Oncologist
; 17(4): 469-75, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22467666
20.
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Breast Cancer Res Treat
; 132(3): 843-51, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21750964